BiotechTube

Apatinib

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer, Randomized Controlled Study

Trial Timeline

Aug 26, 2021 → Mar 3, 2023

NCT ID
NCT05029453

About Apatinib

Apatinib is a approved stage product being developed by Jiangsu Hengrui Medicine for Gastric Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05029453. Target conditions include Gastric Cancer, Randomized Controlled Study.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (20)

NCT IDPhaseStatus
NCT05029453ApprovedUNKNOWN
NCT03709953Phase 2UNKNOWN
NCT03457467Phase 2UNKNOWN
NCT03521219Phase 2UNKNOWN
NCT03390062Phase 2UNKNOWN
NCT03403452Phase 2UNKNOWN
NCT03383237Phase 2UNKNOWN
NCT03376737Phase 2UNKNOWN
NCT03251443Phase 2Completed
NCT03190616Phase 2Completed
NCT03163381Phase 2UNKNOWN
NCT03180476Phase 2Completed
NCT03144856Phase 2UNKNOWN
NCT03170310Phase 2UNKNOWN
NCT02764268Pre-clinicalCompleted
NCT02727309Phase 1/2UNKNOWN
NCT02509806Phase 2/3UNKNOWN
NCT02510469Phase 2/3UNKNOWN
NCT01653561Phase 2Completed
NCT01192971Phase 2Completed

Competing Products

20 competing products in Gastric Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
77
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41

Other Products from Jiangsu Hengrui Medicine

Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85
Bupivacaine Liposome InjectionApproved
85